Recursion Pharmaceuticals, Inc. (RXRX)

Recursion Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	525.11	594.35	391.57	549.91	285.12	262.13
Short-Term Investments	-	-	-	-	231.45	-
Cash & Short-Term Investments	525.11	594.35	391.57	549.91	516.56	262.13
Cash Growth	10.70%	51.79%	-28.79%	6.46%	97.07%	275.09%
Accounts Receivable	-	-	-	-	0.03	0.16
Other Receivables	21.61	49.17	3.09	2.75	9.06	-
Receivables	21.61	49.17	3.09	2.75	9.09	0.16
Restricted Cash	3.11	3.05	3.23	1.28	1.55	2
Other Current Assets	37.34	67.71	40.25	15.87	7.51	2.16
Total Current Assets	587.16	714.27	438.14	569.81	534.72	266.44
Property, Plant & Equipment	193.6	233.21	120.17	121.45	64.73	25.97
Goodwill	164.27	148.87	52.06	0.8	0.8	0.8
Other Intangible Assets	341.32	335.86	36.44	1.31	1.39	1.69
Long-Term Deferred Tax Assets	0.96	1.93	-	-	-	-
Other Long-Term Assets	10.65	14.45	6.89	7.92	8.72	3.69
Total Assets	1,302	1,449	653.7	701.29	610.35	298.59
Accounts Payable	19.31	21.61	3.95	4.59	2.82	1.07
Accrued Expenses	83	80.28	41.76	30.29	27.67	10.49
Current Portion of Long-Term Debt	8.75	0.11	0.04	0.1	0.09	1.07
Current Portion of Leases	11.73	22.11	6.12	5.95	-	-
Current Unearned Revenue	39.69	61.77	36.43	56.73	10	10
Other Current Liabilities	1.54	1.59	4.87	2.62	6.08	0.47
Total Current Liabilities	164.03	187.47	93.17	100.27	46.66	23.1
Long-Term Debt	14.2	0.68	1.1	0.54	0.63	11.41
Long-Term Leases	53.4	85.59	43.41	44.42	-	-
Long-Term Unearned Revenue	126.24	118.77	51.24	70.26	6.67	16.67
Long-Term Deferred Tax Liabilities	23.78	16.58	1.34	-	-	-
Other Long-Term Liabilities	1.57	4.73	-	-	13.45	5.38
Total Liabilities	383.21	413.82	190.26	215.48	67.41	56.56
Common Stock	0	0	0	0	0	-
Additional Paid-In Capital	2,681	2,474	1,431	1,125	943.14	7.31
Retained Earnings	-1,806	-1,431	-967.62	-639.56	-400.08	-213.6
Comprehensive Income & Other	43.62	-7.64	-	-	-0.13	-
Total Common Equity	919.15	1,035	463.44	485.81	542.94	-206.29
Shareholders' Equity	919.15	1,035	463.44	485.81	542.94	242.02
Total Liabilities & Equity	1,302	1,449	653.7	701.29	610.35	298.59
Total Debt	88.08	108.49	50.67	51.01	0.72	12.49
Net Cash (Debt)	437.04	485.86	340.89	498.91	515.84	249.64
Net Cash Growth	13.67%	42.52%	-31.67%	-3.28%	106.63%	335.00%
Net Cash Per Share	1.21	1.77	1.64	2.84	4.12	11.46
Filing Date Shares Outstanding	434.66	401.99	234.65	191.23	170.77	22.31
Total Common Shares Outstanding	432.83	396.8	234.27	191.02	170.27	22.31
Working Capital	423.13	526.8	344.97	469.55	488.06	243.34
Book Value Per Share	2.12	2.61	1.98	2.54	3.19	-9.24
Tangible Book Value	413.56	550.05	374.94	483.7	540.75	-208.78
Tangible Book Value Per Share	0.96	1.39	1.60	2.53	3.18	-9.36
Machinery	-	128.29	82.22	67.69	53.08	20.78
Construction In Progress	-	2.71	3.23	8.75	16.45	1.36
Leasehold Improvements	-	72.73	45.93	41.87	13.94	13.79

Updated Aug 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q